BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
May 19 2021 - 4:15PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
(TSX-V:BCT) (“BriaCell” or the “Company”), a
clinical-stage biotechnology company specializing in targeted
immunotherapy for advanced breast cancer, is pleased to announce
the results of its annual general and special meeting of
shareholders of the Company (the "
Shareholders")
for the years ended July 31, 2019 and July 31, 2020 held on May 18,
2021 (the "
Meeting"). A total of 1,685,180 common
shares of the Company (the "
Common Shares") were
voted, representing 22.36% of the Company's issued and outstanding
Common Shares. At the Meeting, the Shareholders overwhelmingly
voted in favour of all proposed resolutions that consisted of the
following:
-
The number of directors set at six;
-
Election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr.
Charles Wiseman, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony,
and Mr. Martin Schmieg as directors of the Company;
-
Appointment of MNP LLP as auditors of the Company for the ensuing
year and authorizing the directors to fix their remuneration;
-
Renewal of the Company's stock option plan;
-
Ratification of the number of directors set at six for the prior
year ended July 31, 2019;
-
Ratification of the election of Dr. William V. Williams, Mr.
Jamieson Bondarenko, Mr. Richard Berman, Mr. Vaughn C.
Embro-Pantalony, Dr. Rebecca Taub, and Dr. Charles Wiseman as
directors of the Company for the prior year ended July 31,
2019;
-
Ratification of the appointment of MNP LLP as the auditors of the
Company for the prior year ended July 31, 2019 and ratifying the
directors authorization to fix their remuneration;
-
Ratification of the Company’s stock option plan for the prior year
ended July 31, 2019; and
-
Ratification of holding the Company’s annual general and special
meeting for the year ended July 31, 2019 on May 18, 2021.
Having received Shareholder approval, the
Company’s stock option plan remains subject to approval from the
TSX Venture Exchange. The formal report on voting results with
respect to all matters voted upon during the Meeting will be filed
on the Company's SEDAR profile at www.sedar.com.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully in the section titled “Risk Factors” in the Company’s
SEC filings. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics
Corp. undertakes no duty to update such information except as
required under applicable law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
Company Contact:William V. Williams,
MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public
RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024